{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:02:28Z","timestamp":1792512148608,"version":"4.5.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rev Endocr Metab Disord"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s11154-024-09928-3","type":"journal-article","created":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T02:41:00Z","timestamp":1731292860000},"page":"97-111","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Real-world evidence of effectiveness and safety of pasireotide in the treatment of acromegaly: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8837-4343","authenticated-orcid":false,"given":"Betina","family":"Biagetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0519-0072","authenticated-orcid":false,"given":"Marta","family":"Araujo-Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2320-1385","authenticated-orcid":false,"given":"Cristian","family":"Tebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1158-9618","authenticated-orcid":false,"given":"M\u00f3nica","family":"Marazuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6744-7195","authenticated-orcid":false,"given":"Manel","family":"Puig-Domingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,11]]},"reference":[{"key":"9928_CR1","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11154-019-09506-y","volume":"20","author":"F Gatto","year":"2019","unstructured":"Gatto F, Campana C, Cocchiara F, Corica G, Albertelli M, Boschetti M, et al. Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly. Rev Endocr Metab Disord. 2019;20:365\u201381.","journal-title":"Rev Endocr Metab Disord"},{"key":"9928_CR2","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1530\/EJE-20-0019","volume":"182","author":"D Esposito","year":"2020","unstructured":"Esposito D, Ragnarsson O, Johannsson G, Olsson DS. Prolonged diagnostic delay in acromegaly is associated with increased morbidity and mortality. Eur J Endocrinol. 2020;182:523\u201331.","journal-title":"Eur J Endocrinol"},{"key":"9928_CR3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11102-023-01360-1","volume":"27","author":"A Giustina","year":"2024","unstructured":"Giustina A, Biermasz N, Casanueva FF, Fleseriu M, Mortini P, Strasburger C, et al. Consensus on criteria for acromegaly diagnosis and remission. Pituitary. 2024;27:7\u201322.","journal-title":"Pituitary"},{"key":"9928_CR4","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","volume":"14","author":"S Melmed","year":"2018","unstructured":"Melmed S, Bronstein MD, Chanson P, Klibanski A, Casanueva FF, Wass JAH, et al. A Consensus Statement on acromegaly therapeutic outcomes. Nat Reviews Endocrinol. 2018;14:552.","journal-title":"Nat Reviews Endocrinol"},{"key":"9928_CR5","doi-asserted-by":"crossref","unstructured":"Giustina A, Barkan A, Beckers A, Biermasz N, Biller BMK, Boguszewski C et al. A Consensus on the diagnosis and treatment of Acromegaly comorbidities: an update. J Clin Endocrinol Metab. 2019.","DOI":"10.1210\/clinem\/dgz096"},{"key":"9928_CR6","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","volume":"21","author":"A Giustina","year":"2020","unstructured":"Giustina A, Barkhoudarian G, Beckers A, Ben-Shlomo A, Biermasz N, Biller B, et al. Multidisciplinary management of acromegaly: a consensus. Rev Endocr Metab Disord. 2020;21:667\u201378.","journal-title":"Rev Endocr Metab Disord"},{"key":"9928_CR7","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S2213-8587(22)00244-3","volume":"10","author":"M Fleseriu","year":"2022","unstructured":"Fleseriu M, Langlois F, Lim DST, Varlamov EV, Melmed S. Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol. 2022;10:804\u201326.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"9928_CR8","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s12020-018-1590-8","volume":"60","author":"X Antunes","year":"2018","unstructured":"Antunes X, Ventura N, Camilo GB, Wildemberg LE, Guasti A, Pereira PJM, et al. Predictors of surgical outcome and early criteria of remission in acromegaly. Endocrine. 2018;60:415\u201322.","journal-title":"Endocrine"},{"key":"9928_CR9","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1530\/eje.0.1460707","volume":"146","author":"C Bruns","year":"2002","unstructured":"Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol. 2002;146:707\u201316.","journal-title":"Eur J Endocrinol"},{"key":"9928_CR10","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1210\/jc.2013-2480","volume":"99","author":"A Colao","year":"2014","unstructured":"Colao A, Bronstein MD, Freda P, Gu F, Shen C-C, Gadelha M, et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab. 2014;99:791\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"9928_CR11","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","volume":"2","author":"MR Gadelha","year":"2014","unstructured":"Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M, et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2:875\u201384.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"9928_CR12","doi-asserted-by":"crossref","unstructured":"Gadelha M, Marques NV, Fialho C, Scaf C, Lamback E, Antunes X et al. Long-term efficacy and safety of pasireotide in patients with acromegaly: 14 years\u2019 single-center real-world experience. J Clin Endocrinol Metab. 2023;dgad378.","DOI":"10.1210\/clinem\/dgad378"},{"key":"9928_CR13","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/cen.14946","volume":"99","author":"S Ruiz","year":"2023","unstructured":"Ruiz S, Gil J, Biagetti B, Venegas E, C\u00e1mara R, Garcia-Centeno R, et al. Magnetic resonance imaging as a predictor of therapeutic response to pasireotide in acromegaly. Clin Endocrinol (Oxf). 2023;99:378\u201385.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"9928_CR14","doi-asserted-by":"crossref","unstructured":"Urbani C, Dassie F, Zampetti B, Mioni R, Maffei P, Cozzi R et al. Real-life data of Pasireotide LAR in Acromegaly: a long-term follow-up. J Endocrinol Invest. 2024.","DOI":"10.1007\/s40618-023-02275-1"},{"key":"9928_CR15","doi-asserted-by":"crossref","unstructured":"Araujo-Castro M, Biagetti B, Menedez-Torre E, Novoa-Testa I, Cordido F, Pascual-Corrales E et al. Pegvisomant or pasirotide in PRL and GH co-secreting vs GH-secreting Pit-NETs. Endocr Relat Cancer. 2024;ERC-24-0043.","DOI":"10.1530\/ERC-24-0043e"},{"key":"9928_CR16","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"9928_CR17","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.4103\/sja.SJA_543_18","volume":"13","author":"S Cuschieri","year":"2019","unstructured":"Cuschieri S. The STROBE guidelines. Saudi J Anaesth. 2019;13:S31\u20134.","journal-title":"Saudi J Anaesth"},{"key":"9928_CR18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177\u201388.","journal-title":"Control Clin Trials"},{"key":"9928_CR19","unstructured":"R: The R Project for Statistical Computing [Internet]. [cited 2024 Jul 19]. https:\/\/www.r-project.org\/"},{"key":"9928_CR20","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22:153\u201360.","journal-title":"Evid Based Ment Health"},{"key":"9928_CR21","doi-asserted-by":"crossref","unstructured":"Corica G, Pirchio R, Milioto A, Nista F, Arecco A, Mattioli L et al. Pasireotide effects on biochemical control and glycometabolic profile in acromegaly patients switched from combination therapies or unconventional dosages of somatostatin analogs. J Endocrinol Invest. 2023.","DOI":"10.1007\/s40618-023-02186-1"},{"key":"9928_CR22","doi-asserted-by":"crossref","first-page":"1344728","DOI":"10.3389\/fendo.2024.1344728","volume":"15","author":"V Favero","year":"2024","unstructured":"Favero V, Zampetti B, Carioni EI, Dalino Ciaramella P, Grossrubatscher E, Dallabonzana D, et al. Efficacy of pasireotide LAR for acromegaly: a prolonged real-world monocentric study. Front Endocrinol (Lausanne). 2024;15:1344728.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"9928_CR23","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s12020-022-03158-w","volume":"78","author":"S Chiloiro","year":"2022","unstructured":"Chiloiro S, Costa D, Lauretta R, Mercuri V, Sbardella E, Samperi I, et al. Partial response to first generation SSA guides the choice and predict the outcome of second line therapy in acromegaly. Endocrine. 2022;78:343\u201353.","journal-title":"Endocrine"},{"key":"9928_CR24","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1007\/s12020-021-02711-3","volume":"73","author":"S Chiloiro","year":"2021","unstructured":"Chiloiro S, Giampietro A, Visconti F, Rossi L, Donfrancesco F, Fleseriu CM, et al. Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant. Endocrine. 2021;73:658\u201366.","journal-title":"Endocrine"},{"key":"9928_CR25","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1530\/EJE-20-0767","volume":"184","author":"S Chiloiro","year":"2021","unstructured":"Chiloiro S, Giampietro A, Mirra F, Donfrancesco F, Tartaglione T, Mattogno PP, et al. Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response. Eur J Endocrinol. 2021;184:217\u201329.","journal-title":"Eur J Endocrinol"},{"key":"9928_CR26","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1530\/EJE-15-0832","volume":"174","author":"D Iacovazzo","year":"2016","unstructured":"Iacovazzo D, Carlsen E, Lugli F, Chiloiro S, Piacentini S, Bianchi A, et al. Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. Eur J Endocrinol. 2016;174:241\u201350.","journal-title":"Eur J Endocrinol"},{"key":"9928_CR27","doi-asserted-by":"crossref","unstructured":"Pirchio R, Auriemma RS, Vergura A, Pivonello R, Colao A. Long-term pasireotide therapy in acromegaly: extensive real-life experience of a referral center. J Endocrinol Invest. 2024.","DOI":"10.1007\/s40618-023-02299-7"},{"key":"9928_CR28","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s12020-020-02306-4","volume":"69","author":"EC Coopmans","year":"2020","unstructured":"Coopmans EC, El-Sayed N, Frystyk J, Magnusson NE, J\u00f8rgensen JOL, van der Lely A-J, et al. Soluble Klotho: a possible predictor of quality of life in acromegaly patients. Endocrine. 2020;69:165\u201374.","journal-title":"Endocrine"},{"key":"9928_CR29","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1530\/EJE-19-0840","volume":"182","author":"EC Coopmans","year":"2020","unstructured":"Coopmans EC, Schneiders JJ, El-Sayed N, Erler NS, Hofland LJ, van der Lely A-J, et al. T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly. Eur J Endocrinol. 2020;182:595\u2013605.","journal-title":"Eur J Endocrinol"},{"key":"9928_CR30","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1530\/EJE-18-0353","volume":"179","author":"A Muhammad","year":"2018","unstructured":"Muhammad A, Coopmans EC, Delhanty PJD, Dallenga AHG, Haitsma IK, Janssen JAMJL, et al. Efficacy and safety of switching to Pasireotide in Acromegaly patients controlled with pegvisomant and somatostatin analogues: PAPE extension study. Eur J Endocrinol. 2018;179:269\u201377.","journal-title":"Eur J Endocrinol"},{"key":"9928_CR31","doi-asserted-by":"crossref","unstructured":"Muhammad A, Van der Janssen LAJ, Neggers J. S. Efficacy and safety of switching to pasireotide LAR alone or in combination with pegvisomant in acromegaly patients controlled with combination treatment of first-generation somatostatin analogues and weekly pegvisomant (PAPE study): a prospective open-label 48 week study, preliminary results 24 weeks. 2017 [cited 2017 Sep 24]; http:\/\/www.endocrine-abstracts.org\/ea\/0049\/ea0049GP174.htm","DOI":"10.1530\/endoabs.49.GP174"},{"key":"9928_CR32","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s12020-016-1182-4","volume":"55","author":"M Fleseriu","year":"2017","unstructured":"Fleseriu M, Rusch E, Geer EB, ACCESS Study Investigators. Safety and tolerability of pasireotide long-acting release in acromegaly-results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study. Endocrine. 2017;55:247\u201355.","journal-title":"Endocrine"},{"key":"9928_CR33","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s11102-021-01185-w","volume":"25","author":"M Stelmachowska-Bana\u015b","year":"2022","unstructured":"Stelmachowska-Bana\u015b M, Czajka-Oraniec I, Tomasik A, Zgliczy\u0144ski W. Real-world experience with pasireotide-LAR in resistant acromegaly: a single center 1-year observation. Pituitary. 2022;25:180\u201390.","journal-title":"Pituitary"},{"key":"9928_CR34","doi-asserted-by":"crossref","first-page":"633944","DOI":"10.3389\/fendo.2021.633944","volume":"12","author":"P Witek","year":"2021","unstructured":"Witek P, Bolanowski M, Szamotulska K, Wojciechowska-Lu\u017aniak A, Jawiarczyk-Przyby\u0142owska A, Ka\u0142u\u017cny M. The Effect of 6 months\u2019 treatment with pasireotide LAR on glucose metabolism in patients with resistant acromegaly in real-world clinical settings. Front Endocrinol (Lausanne). 2021;12:633944.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"9928_CR35","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s12020-021-02782-2","volume":"74","author":"A Akirov","year":"2021","unstructured":"Akirov A, Gorshtein A, Dotan I, Khazen NS, Pauker Y, Gershinsky M, et al. Long-term safety and efficacy of long-acting pasireotide in acromegaly. Endocrine. 2021;74:396\u2013403.","journal-title":"Endocrine"},{"key":"9928_CR36","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.4158\/EP-2020-0171","volume":"26","author":"H Masri-Iraqi","year":"2020","unstructured":"Masri-Iraqi H, Akirov A, Shimon I. Medical Treatment Landscape for active acromegaly in a Pituitary Center in Israel. Endocr Pract. 2020;26:1298\u2013303.","journal-title":"Endocr Pract"},{"key":"9928_CR37","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s12020-018-1690-5","volume":"62","author":"I Shimon","year":"2018","unstructured":"Shimon I, Adnan Z, Gorshtein A, Baraf L, Saba Khazen N, Gershinsky M, et al. Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study. Endocrine. 2018;62:448\u201355.","journal-title":"Endocrine"},{"key":"9928_CR38","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1507\/endocrj.EJ16-0624","volume":"64","author":"S Tahara","year":"2017","unstructured":"Tahara S, Murakami M, Kaneko T, Shimatsu A. Efficacy and safety of long-acting pasireotide in Japanese patients with acromegaly or pituitary gigantism: results from a multicenter, open-label, randomized, phase 2 study. Endocr J. 2017;64:735\u201347.","journal-title":"Endocr J"},{"key":"9928_CR39","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3389\/fendo.2019.00931","volume":"10","author":"M Gadelha","year":"2019","unstructured":"Gadelha M, Bex M, Colao A, Pedroza Garc\u00eda EM, Poiana C, Jimenez-Sanchez M, et al. Evaluation of the efficacy and safety of switching to Pasireotide in patients with acromegaly inadequately controlled with First-Generation somatostatin analogs. Front Endocrinol (Lausanne). 2019;10:931.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"9928_CR40","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1530\/EC-19-0332","volume":"8","author":"H Lasolle","year":"2019","unstructured":"Lasolle H, Ferriere A, Vasiljevic A, Eimer S, Nunes M-L, Tabarin A. Pasireotide-LAR in acromegaly patients treated with a combination therapy: a real-life study. Endocr Connect. 2019;8:1383\u201394.","journal-title":"Endocr Connect"},{"key":"9928_CR41","doi-asserted-by":"crossref","first-page":"e220296","DOI":"10.1530\/EC-22-0296","volume":"11","author":"P Wolf","year":"2022","unstructured":"Wolf P, Dormoy A, Maione L, Salenave S, Young J, Kamenick\u00fd P, et al. Impairment in insulin secretion without changes in insulin resistance explains hyperglycemia in patients with acromegaly treated with pasireotide LAR. Endocr Connect. 2022;11:e220296.","journal-title":"Endocr Connect"},{"key":"9928_CR42","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/s11102-016-0734-1","volume":"19","author":"JM Silverstein","year":"2016","unstructured":"Silverstein JM. Hyperglycemia induced by pasireotide in patients with Cushing\u2019s disease or acromegaly. Pituitary. 2016;19:536\u201343.","journal-title":"Pituitary"},{"key":"9928_CR43","doi-asserted-by":"crossref","unstructured":"Jepsen SL, Albrechtsen NJW, Windel\u00f8v JA, Galsgaard KD, Hunt JE, Farb TB et al. Antagonizing somatostatin receptor subtype 2 and 5 reduces blood glucose in a gut- and GLP-1R\u2013dependent manner. JCI Insight [Internet]. 2021 [cited 2024 Jul 20];6. https:\/\/insight.jci.org\/articles\/view\/143228","DOI":"10.1172\/jci.insight.143228"},{"key":"9928_CR44","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s11154-022-09710-3","volume":"23","author":"M Bolanowski","year":"2022","unstructured":"Bolanowski M, Ka\u0142u\u017cny M, Witek P, Jawiarczyk-Przyby\u0142owska A. Pasireotide-a novel somatostatin receptor ligand after 20 years of use. Rev Endocr Metab Disord. 2022;23:601\u201320.","journal-title":"Rev Endocr Metab Disord"},{"key":"9928_CR45","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1210\/jc.2017-00135","volume":"102","author":"F Gatto","year":"2017","unstructured":"Gatto F, Feelders RA, Franck SE, van Koetsveld PM, Dogan F, Kros JM, et al. In Vitro Head-to-head comparison between Octreotide and Pasireotide in GH-Secreting pituitary adenomas. J Clin Endocrinol Metab. 2017;102:2009\u201318.","journal-title":"J Clin Endocrinol Metab"},{"key":"9928_CR46","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1530\/EJE-08-0267","volume":"159","author":"IM Holdaway","year":"2008","unstructured":"Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol. 2008;159:89\u201395.","journal-title":"Eur J Endocrinol"},{"key":"9928_CR47","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s11102-015-0700-3","volume":"19","author":"L Varadhan","year":"2016","unstructured":"Varadhan L, Reulen RC, Brown M, Clayton RN. The role of cumulative growth hormone exposure in determining mortality and morbidity in acromegaly: a single centre study. Pituitary. 2016;19:251\u201361.","journal-title":"Pituitary"},{"key":"9928_CR48","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/cen.15060","volume":"100","author":"S Orme","year":"2024","unstructured":"Orme S, McNally R, James PW, Davis J, Ayuk J, Higham C, et al. Increased mortality in acromegaly is due to vascular and respiratory disease and is normalised by control of GH levels-A retrospective analysis from the UK Acromegaly Register 1970\u20132016. Clin Endocrinol (Oxf). 2024;100:558\u201364.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"9928_CR49","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1210\/jc.2014-2670","volume":"99","author":"M Mercado","year":"2014","unstructured":"Mercado M, Gonzalez B, Vargas G, Ramirez C, de los Monteros ALE, Sosa E, et al. Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic. J Clin Endocrinol Metab. 2014;99:4438\u201346.","journal-title":"J Clin Endocrinol Metab"},{"key":"9928_CR50","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.yfrne.2013.07.005","volume":"34","author":"M Theodoropoulou","year":"2013","unstructured":"Theodoropoulou M, Stalla GK. Somatostatin receptors: from signaling to clinical practice. Front Neuroendocrinol. 2013;34:228\u201352.","journal-title":"Front Neuroendocrinol"},{"key":"9928_CR51","doi-asserted-by":"crossref","first-page":"9244","DOI":"10.1074\/jbc.275.13.9244","volume":"275","author":"D Liu","year":"2000","unstructured":"Liu D, Martino G, Thangaraju M, Sharma M, Halwani F, Shen S-H, et al. Caspase-8-mediated intracellular acidification precedes mitochondrial dysfunction in somatostatin-induced Apoptosis*. J Biol Chem. 2000;275:9244\u201350.","journal-title":"J Biol Chem"},{"key":"9928_CR52","doi-asserted-by":"crossref","unstructured":"Lee M, Lupp A, Mendoza N, Martin N, Beschorner R, Honegger J et al. SSTR3 is a putative target for the medical treatment of gonadotroph adenomas of the pituitary. 2015 [cited 2024 Jul 25]; https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/22\/1\/111.xml","DOI":"10.1530\/ERC-14-0472"},{"key":"9928_CR53","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1530\/eje.1.02313","volume":"156","author":"GF Taboada","year":"2007","unstructured":"Taboada GF, Luque RM, Bastos W, Guimar\u00e3es RFC, Marcondes JB, Chimelli LMC, et al. Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. Eur J Endocrinol. 2007;156:65\u201374.","journal-title":"Eur J Endocrinol"},{"key":"9928_CR54","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1530\/EJE-07-0562","volume":"158","author":"GF Taboada","year":"2008","unstructured":"Taboada GF, Luque RM, Neto LV, Machado E, de O, Sbaffi BC, Domingues RC, et al. Quantitative analysis of somatostatin receptor subtypes (1\u20135) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. Eur J Endocrinol. 2008;158:295\u2013303.","journal-title":"Eur J Endocrinol"},{"key":"9928_CR55","first-page":"3268","volume":"84","author":"P Jaquet","year":"1999","unstructured":"Jaquet P, Ouafik L, Saveanu A, Gunz G, Fina F, Dufour H, et al. Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas. J Clin Endocrinol Metab. 1999;84:3268\u201376.","journal-title":"J Clin Endocrinol Metab"},{"key":"9928_CR56","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1210\/jc.2013-1771","volume":"98","author":"RR Henry","year":"2013","unstructured":"Henry RR, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan M, Mudaliar S. Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab. 2013;98:3446\u201353.","journal-title":"J Clin Endocrinol Metab"},{"key":"9928_CR57","doi-asserted-by":"crossref","first-page":"bvad1141134","DOI":"10.1210\/jendso\/bvad114.1134","volume":"7","author":"SL Samson","year":"2023","unstructured":"Samson SL, Bolanowski M, Zhang S-L, Yu Y, Witek P, Kietsiriroje N, et al. THU054 a Post Hoc analysis of the phase IV B2219 study to determine predictive factors for Hyperglycemia during Treatment with Pasireotide. J Endocr Soc. 2023;7:bvad1141134.","journal-title":"J Endocr Soc"},{"key":"9928_CR58","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1530\/EC-20-0361","volume":"9","author":"MR Gadelha","year":"2020","unstructured":"Gadelha MR, Gu F, Bronstein MD, Brue TC, Fleseriu M, Shimon I, et al. Risk factors and management of pasireotide-associated hyperglycemia in acromegaly. Endocr Connect. 2020;9:1178\u201390.","journal-title":"Endocr Connect"},{"key":"9928_CR59","doi-asserted-by":"crossref","first-page":"1348990","DOI":"10.3389\/fendo.2024.1348990","volume":"15","author":"S St\u00f6rmann","year":"2024","unstructured":"St\u00f6rmann S, Meyh\u00f6fer SM, Groener JB, Faust J, Schilbach K, Seufert J, et al. Management of pasireotide-induced hyperglycemia in patients with acromegaly: an experts\u2019 consensus statement. Front Endocrinol (Lausanne). 2024;15:1348990.","journal-title":"Front Endocrinol (Lausanne)"}],"updated-by":[{"DOI":"10.1007\/s11154-024-09935-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000}}],"container-title":["Reviews in Endocrine and Metabolic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-024-09928-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11154-024-09928-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-024-09928-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T23:38:06Z","timestamp":1738539486000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11154-024-09928-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,11]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["9928"],"URL":"https:\/\/doi.org\/10.1007\/s11154-024-09928-3","relation":{},"ISSN":["1389-9155","1573-2606"],"issn-type":[{"value":"1389-9155","type":"print"},{"value":"1573-2606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,11]]},"assertion":[{"value":"4 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2024","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"To update Figure 4, parts (a) and (b) overlap, resulting in the lower section of Figure 4a being hidden.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2024","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11154-024-09935-4","URL":"https:\/\/doi.org\/10.1007\/s11154-024-09935-4","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"B.B., MA, MM and M.P.D. have received consulting fees, research support, or participated in clinical trials supported by Pfizer, Ipsen, and\/or Recordati. C.T. has received fees for speaker lectures from Gedeon Richte.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}